The Medical Letter on Drugs and Therapeutics
Nebivolol (Bystolic) for Hypertension
The full article is available to subscribers Subscriber Login   

Nebivolol (Bystolic – Forest) is a new beta-blocker that has been approved by the FDA for treatment of hypertension. It has been marketed in Europe since 1999 for treatment of hypertension and heart failure.

PHARMACOLOGY — Like carvedilol and labetalol, nebivolol has vasodilating as well as beta-blocking effects, but unlike the other two drugs, which have alpha-blocking properties, nebivolol has nitric oxidemediated vasodilatory effects.1 At doses of up to 10 mg, nebivolol selectively antagonizes beta1-adrenergic receptors, causing a decrease in heart rate, myocardial contractility and renin activity. At higher doses, it antagonizes beta2 receptors and could cause bronchospasm and other symptoms as well. It has no intrinsic sympathomimetic activity. Nebivolol is highly lipophilic. Unlike some other beta-blockers, it apparently does not increase insulin ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Nebivolol (Bystolic) for Hypertension
Article code: 1281a
 Electronic, downloadable article - $25